

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David HAIGH et al.

Serial No.: 10/531,884

Group Art Unit: 1626

File Date: April 11, 2006

Examiner: Cheng, Karen

For: *1-Acyl-Pyrrolidine Derivatives For The Treatment Of Viral Infections*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed.

☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No. _____


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(6).
- ☐ The petition fee set forth in § 1.17(d)(1) (\$150.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No. 07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Karen L. Prus

Registration No. 39,337

Date: April 27, 2007

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2192

Facsimile: (919) 483-7988

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10531884
Filing Date	2006-04-11
First Named Inventor	David HAIGH
Art Unit	1626
Examiner Name	Cheng, Karen
Attorney Docket Number	PG4890USw

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6378712		1995-01-03	Alg L., et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ²	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ³
	1	9929705	WO	A2	1999-06-17	Glycomed Incorporated		<input type="checkbox"/>
	2	99/37304	WO	A1	1999-07-29	RHONE-POULENC RORER PHARMACEUTICALS INC		<input type="checkbox"/>
	3	2002/44166	WO	A2	2002-06-06	SCIOS INC.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10531884
Filing Date	2006-04-11
First Named Inventor	David HAIGH
Art Unit	1628
Examiner Name	Cheng, Karen
Attorney Docket Number	PG4890USw

4	99/33170	WO	A1	1999-10-24	CIBA-GEIGY AG	<input type="checkbox"/>
5	2004037818	WO	A1	2004-05-06	Glaxo Group Limited	<input type="checkbox"/>
6	03037893	WO		2003-05-08		<input type="checkbox"/>
7	03037895	WO	A1	2003-05-08	Glaxo Group Limited	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T#
	1	SATO ET AL; Heterocycles; 1994; 37/1; 245-248;	<input type="checkbox"/>
	2	P. DE CAPRARIIS, G DE MARTINO, E. ABIGNENTE, P AVARA, L MAYO; Pyrrolo[1,4]benzodiazepines. IV Synthesis of E- and Z-6,11-Dioxo-11a-ethoxycarbonyl-2-ethylidene-1,2,3,10,11,11a-hexahydro-5Hpyrrolo[2,1-c][1,4]benzodiazepine; J. Heterocyclic Chem.; Jan 89; 26; 1023-1027;	<input type="checkbox"/>
	3	GARDINER, JAMES ET AL; Synthesis and solid state conformation of phenylalanine mimetics constrained in a proline-like conformation; Organic & Biomolecular Chemistry; 27 July 2004; 2(16); 2365-2370;	<input type="checkbox"/>
	4	IKEDA M., ET AL.; Synthesis of tricyclic nitrogen-containing heterocycles by palladium-catalyzed cyclization of 2-alkenyl-N-(o-iodobenzoyl)- and 2-alkenyl-N-(o-iodophenylacetyl)-pyrrolidines; Heterocycles; 1998; 42; pgs. 155-158;	<input type="checkbox"/>
	5	CONFALONE P.N., ET AL.; Design and synthesis of potential DNA cross-linking reagents based on the anthramycin class of minor groove binding compounds; J. Org. Chem.; 1988; 53; pgs. 482-487;	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10531884
Filing Date	2006-04-11
First Named Inventor	David HAIGH
Art Unit	1828
Examiner Name	Cheng, Karen
Attorney Docket Number	PG4890USw

6	ALIG L., ET AL.; Low molecular weight, non-peptide fibrinogen receptor antagonists; J. Med. Chem.; 1992; 35; pgs. 4393-4407;	<input type="checkbox"/>
7	PADWA A., ET AL.; Transmutations of 1,2-dipoles. The conversion of α -diazo ketones into azomethine ylides via carbonyl ylides; J. Am. Chem. Soc.; 1992; 114; pgs. 593-601;	<input type="checkbox"/>
8	CULBERTSON T.P., ET AL.; Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships; J. Med. Chem.; 1990; 33; pgs. 2270-2275;	<input type="checkbox"/>
9	CROOKS, P.A., ET AL.; Synthesis of 5-hydroxy- and 5,6-dihydroxy-derivatives of spiro[indane-2,2'-pyrrolidine], rigid analogues of tyramine and dopamine respectively; Journal of the Chemical Society, Perkins Transactions 1; 1979; 11; pgs. 2719-2726;	<input type="checkbox"/>
10	DE MARTINO G., ET AL.; La Reazione Tra 2-Nitrobenzotriaminomalonato Ed Aldeide Acrilica Per LA Sintesi Di Composti A Struttura Pirolo[2,1-c][1,4]Benzodiazapirina (english summary only); Farmaco Ed Sc.; 1976; 31(11); pgs. 785-790;	<input type="checkbox"/>
11	IKEDA ET AL.; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry; 1997; 22; 3336-3344;	<input type="checkbox"/>
12	SATO ET AL.; Journal of the Chemical Society, Perkin Transactions 1; 1995; 14; 1801-1809;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.